Beijing Mabworks Biotech
Beijing Mabworks Biotech is a Chinese developer in Beijing that sponsors 4 registered cancer trials of MBS314 and MBS303.
Overview
Beijing Mabworks Biotech appears on ClinicalTrials.gov as the industry sponsor of 4 interventional cancer trials (phase 1/2, 3), testing MBS314, MBS303, Recombinant Humanized Monoclonal Antibody MIL62, lenalinomide, lenalinomide in relapsed or refractory multiple myeloma, non-hodgkin's lymphoma, follicular lymphoma and marginal zone lymphoma. OnCo records the company from the registry alone: the head office city comes from its registered name, and there are no website, funding or approval claims until they are sourced.
Similar pages
not linked directly; found by shared links- CompanyBeijing Gene Key Life Technology
Shares the tags china, registry-only.
- CompanyBeijing Konruns Pharmaceutical
Shares the tags china, registry-only.
- CompanyBeijing Pearl Biotechnology Limited Liability Company
Shares the tags china, registry-only.
- CompanyBeijing Scitech-Mq Pharmaceuticals
Shares the tags china, registry-only.
- CompanyBeijing Tide Pharmaceutical
Shares the tags china, registry-only.
- CompanyBinhui Biopharmaceutical
Shares the tags china, registry-only.
- CompanyChengdu Zenitar Biomedical Technology
Shares the tags china, registry-only.
- CompanyHenan Genuine Biotech
Shares the tags china, registry-only.